RxDoctor Payments Data

Franklin Fuenmayor-Cardozo, MD

Nephrology · Macon, GANPI 1467659854

Payments from drug & device makers

$5,738in general payments, 2019–2025

Across 221 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$730
  • Aurinia Pharma U.S., Inc.$523
  • Bayer$495
  • Akebia Therapeutics Inc$399
  • Travere Therapeutics, Inc.$399
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,25592%
  • Education$4838%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,738 in reported general payments places this provider in the 75th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$534,180
Medicare patients
660
Services billed
4,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol591$411,122
RayaldeeCalcifediol71$102,137
JardianceEmpagliflozin119$87,593
VelphoroSucroferric Oxyhydroxide22$53,057
KerendiaFinerenone57$49,290
EliquisApixaban54$41,022
OzempicSemaglutide34$38,811
VeltassaPatiromer Calcium Sorbitex14$13,410
Sevelamer Carbonate73$13,096
DapagliflozinDapagliflozin Propanediol17$7,802
LinzessLinaclotide11$5,887
Calcium Acetate41$4,264
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,714
Losartan Potassium391$2,253
Furosemide558$2,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,088$411,122591 claims
OPKO Pharmaceuticals, LLCRayaldee$81$102,13771 claims
Boehringer IngelheimJardiance$76$87,593119 claims
Fresenius USA Marketing, Inc.Velphoro$282$53,05722 claims
BayerKerendia$495$49,29057 claims
Novo NordiskOzempic$80$38,81134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 nephrology providers in Georgia.

Other nephrology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →